Bookmark
Forward
Explore Curated Studies Results
Explore Literature Results
Explore Clinical Trials Results
QuickView for direct thrombin inhibitor (compound)
Most Correlated Studies
- Drug target sets for approved compounds
- L1000 CMAP - Colorectal cancer HT29 cells treated with ligand perturbagens
- L1000 CMAP - Prostate carcinoma VCaP cells treated with ligand perturbagens
- L1000 CMAP - Lung cancer A549 cells treated with ligand perturbagens
- L1000 CMAP - Adenocarcinoma of breast MCF7 cells treated with ligand perturbagens
Most Relevant Literature
- Antithrombin Deficiency: Frequency in Patients with Thrombosis and Thrombophilic Families.
- A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Preoperative Antithrombin Suppl…
- Correlation of Antithrombin Functional Status and Levels with Liver Fibrosis in Patients with Hepati…
- Anticoagulant Use During Extracorporeal Membrane Oxygenation Using Heparin and Direct Thrombin Inhib…
- Direct thrombin inhibitors as alternatives to heparin to preserve lung growth and function in a muri…
Most Relevant Clinical Trials
- Direct Thrombin Inhibitors Versus LMWH in Staphylococcus Aureus Bacteraemia
- Twice-daily Oral Direct Thrombin Inhibitor Dabigatran Etexilate in the Long Term Prevention of Recur…
- Thrombin Regulated Platelet Activation
- Influence of Vorapaxar on Thrombin Generation and Coagulability
- Apixaban + DAPT in Lowering Platelet Reactivity and Thrombin Generation
